Adding to this, we found that a quarter of breast cancer patients harbor RSPO2 or RSPO3 copy number amplification, which is associated with high tumor grade, ER and PR negative status, and reduced survival, indicating the clinical relevance of RSPO. This evidence concerns the gene ESR1 and breast cancer.